TNFRSF8 and hematopoietic and lymphoid cell neoplasm: Regarding hematologic cancers, a phase I clinical trial with a bispecific monoclonal antibody simultaneously targeting CD16 and the Hodgkin and Reed-Sternberg cell-associated CD30 antigen (HRS-3/A9) showed one complete and one partial remission (CR/PR) out of 9 patients [30].